Advertisement
Advertisement
ZLAB
Zai Lab Limited - ADR
20.34
USDSponsored
+1.53
+8.13%
Apr 01, 15:59 UTC -4
Closed
After-Market
20.55
+0.21
+1.05%
ZLAB Earnings Reports
Positive Surprise Ratio
ZLAB beat 14 of 18 last estimates.
78%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$116.33M
/-$0.04
Implied change from Q4 25 (Revenue/ EPS)
-8.46%
/-20.00%
Implied change from Q1 25 (Revenue/ EPS)
+9.25%
/--
Zai Lab Limited - ADR earnings per share and revenue
On Feb 26, 2026, ZLAB reported earnings of -0.05 USD per share (EPS) for Q4 25, beating the estimate of -0.06 USD, resulting in a 24.01% surprise. Revenue reached 127.09 million, compared to an expected 126.96 million, with a 0.10% difference. The market reacted with a +1.55% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.04 USD, with revenue projected to reach 116.33 million USD, implying an decrease of -20.00% EPS, and decrease of -8.46% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.08
Surprise
-16.19%
Bicara Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.68
Actual
-$0.68
Surprise
+0.66%
Neumora Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.33
Actual
-$0.35
Surprise
-5.39%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.17
Surprise
+7.41%
Sangamo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-14.38%
RenovoRx, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
INmune Bio Inc. Common stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
PDS Biotechnology Corporation Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.14
Surprise
+27.76%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-17.65%
Lantern Pharma Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.36
Surprise
+23.27%
FAQ
What were Zai Lab Limited - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Zai Lab Limited - ADR reported EPS of -$0.05, beating estimates by 24.01%, and revenue of $127.09M, 0.1% above expectations.
How did the market react to Zai Lab Limited - ADR's Q4 2025 earnings?
The stock price moved up 1.55%, changed from $19.39 before the earnings release to $19.69 the day after.
When is Zai Lab Limited - ADR expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Zai Lab Limited - ADR's next earnings report?
Based on --
analysts, Zai Lab Limited - ADR is expected to report EPS of -$0.04 and revenue of $116.33M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement